Tumor antigen vaccine

Global $7.61 Billion Cancer Vaccines (Preventive, Therapeutic) Markets, 2015-2019, 2023F, 2025F, 2030F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 29, 2021
Pharmaceutical, Health, Oncology, Vaccination, Medical specialties, Clinical medicine, Medicine, Cancer vaccines, Vaccines, Virology, Vaccine, Cancer vaccine, Vaccine therapy, Tumor antigen vaccine

Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.

Key Points: 
  • Cancer Vaccines Global Market Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cancer vaccines global market market.
  • The cancer vaccines market consists of sales of vaccines used for the treatment of cancers and related services by entities (organizations, sole traders and partnerships) that produce vaccines for cancer treatment.
  • The cancer vaccines market covered in this report is segmented by type into preventive cancer vaccines; therapeutic cancer vaccines.
  • It is also segmented by technology into dendritic cells (DC) cancer vaccines; recombinant cancer vaccines; antigen/adjuvant cancer vaccines; whole cell cancer vaccines; viral vector & DNA cancer vaccines, by cancer type into prostate; cervical; colorectal; throat; others and by end-user into cancer treatment centers; research institutes.

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medicine, Medical specialties, Vaccines, Cancer vaccine, Vaccination, Cancer vaccines, Biotechnology, Genomics, Tumor antigen vaccine, Cancer immunotherapy

The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.

Key Points: 
  • The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.
  • The patient received a vaccine comprising of 30 tumor antigens including 27 cancer neoantigens and 3 shared antigens.
  • "We are encouraged by the interim data from our personalized cancer vaccine program showing tumor shrinkage in combination with anti-PD1.
  • At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment.

Worldwide Cancer Vaccines Industry to 2026 - Featuring AstraZeneca, GlaxoSmithKline and Moderna Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Pharmaceutical, Health, Oncology, Vaccination, Medical specialties, Clinical medicine, Medicine, Cancer vaccine, Vaccine, Cancer, Tumor antigen vaccine, Cancer prevention

Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination.

Key Points: 
  • Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination.
  • The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.
  • Providence Therapeutics is a Toronto based clinical stage biotechnology company that develops cancer vaccines for human use.
  • Currently company is developing a personalized mRNA cancer vaccine designed to generate strong T cell responses that aim to kill cancer cells and destroy tumors in ovarian cancer, breast cancer and brain cancer.

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021
Vaccination, Medical specialties, Vaccines, Medicine, Clinical medicine, Vaccine, Virology, Tumor antigen vaccine, Cancer vaccine, Medical research, Papillomavirus, Tonix Pharmaceuticals

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021
Vaccination, Medical specialties, Vaccines, Medicine, Clinical medicine, Vaccine, Virology, Tumor antigen vaccine, Cancer vaccine, Medical research, Papillomavirus, Tonix Pharmaceuticals

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

Global Peptide Cancer Vaccine Market Clinical Trials Research Outlook 2026

Retrieved on: 
Thursday, April 22, 2021
Medicine, Clinical medicine, Vaccines, Medical specialties, Vaccination, Vaccine, Virology, Cancer vaccines, Peptide vaccine, Medical research, Tumor antigen vaccine, Gp100:209-217

b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.
  • Currently, GV10001 is the only peptide based vaccine approved in Korea for the management of pancreatic cancer.
  • The high growth rate is mainly attributed to the high prevalence of cancer, robust clinical pipeline of vaccines and the safety and cost-efficacy of peptide based vaccines.\nIn terms of geography, it is expected that North America will dominate the global peptide cancer vaccine market landscape after the commercial launch of first peptide cancer vaccine in the region.
  • In coming years, the market will witness rapid approval of several peptide based cancer vaccines which will boost the growth of market.

Global Peptide Cancer Vaccine Market Clinical Trials Research Outlook 2026

Retrieved on: 
Thursday, April 22, 2021
Medicine, Clinical medicine, Vaccines, Medical specialties, Vaccination, Vaccine, Virology, Cancer vaccines, Peptide vaccine, Medical research, Tumor antigen vaccine, Gp100:209-217

b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" Report Highlights:\nGlobal Peptide Cancer Drugs Market Opportunity: >USD 20 Billion\nGlobal Peptide Cancer Vaccine Clinical Trials Insight By Company, Indication & Phase\nNumber Of Peptide Vaccines In Pipeline: >90\n"Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global Peptide Cancer Vaccine market and its impact on the global pharmaceutical market landscape.
  • Currently, GV10001 is the only peptide based vaccine approved in Korea for the management of pancreatic cancer.
  • The high growth rate is mainly attributed to the high prevalence of cancer, robust clinical pipeline of vaccines and the safety and cost-efficacy of peptide based vaccines.\nIn terms of geography, it is expected that North America will dominate the global peptide cancer vaccine market landscape after the commercial launch of first peptide cancer vaccine in the region.
  • In coming years, the market will witness rapid approval of several peptide based cancer vaccines which will boost the growth of market.

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Biology, Oncology, Oncogenes, Apoptosis, Programmed cell death, Gene expression, Survivin, Bcl-2, Cancer, Tumor antigen vaccine

ST101 significantly decreases the expression of C/EBP target genes/proteins involved in cell survival, proliferation and differentiation including BCL-2, MCL-1, BIRC5/survivin, cyclins and ID family of proteins.

Key Points: 
  • ST101 significantly decreases the expression of C/EBP target genes/proteins involved in cell survival, proliferation and differentiation including BCL-2, MCL-1, BIRC5/survivin, cyclins and ID family of proteins.
  • ST101 has been demonstrated to induce selective cancer cell cytotoxicity across a variety of tumor types, including but not limited to breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML.
  • C/EBP is expressed and active in cancer cells but not active in normal cells (post-differentiation), providing a therapeutic opportunity.
  • Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers.

Global Dendritic Cell Cancer Vaccine Immunotherapy Market Report 2026

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Medicine, Clinical medicine, Vaccination, Vaccine, Immunotherapy, Cancer vaccine, Dendritic cell, Tumor antigen vaccine, Therapeutic vaccines

NEW DELHI, March 24, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    The field of science, technology and pharmaceutical sector is highly influenced by the overall progress that is made in the therapeutics industry.
  • The arrival of global dendritic cancer cell vaccine for the patients suffering from different types of cancers is estimated to deliver significant opportunities to millions of patient population.
  • To all the already available cancer therapies, dendritic cancer cell vaccine is delivering a threat in terms of total sales of the drugs and net market growth rate.
  • As per "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" findings, it is estimated that the market carries complete ability to over-shadow the challenges that were limiting the growth of the cancer therapeutics market at global level.

Global Dendritic Cell Cancer Vaccine Immunotherapy Market Report 2026

Retrieved on: 
Wednesday, March 24, 2021
Medical specialties, Medicine, Clinical medicine, Vaccination, Vaccine, Immunotherapy, Cancer vaccine, Dendritic cell, Tumor antigen vaccine, Therapeutic vaccines

NEW DELHI, March 24, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 24, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    The field of science, technology and pharmaceutical sector is highly influenced by the overall progress that is made in the therapeutics industry.
  • The arrival of global dendritic cancer cell vaccine for the patients suffering from different types of cancers is estimated to deliver significant opportunities to millions of patient population.
  • To all the already available cancer therapies, dendritic cancer cell vaccine is delivering a threat in terms of total sales of the drugs and net market growth rate.
  • As per "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" findings, it is estimated that the market carries complete ability to over-shadow the challenges that were limiting the growth of the cancer therapeutics market at global level.